RTALB.E — RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
TRY1.51bn
Enterprise Value
TRY1.66bn
Revenue
TRY95.94m

Annual income statement for RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	16.8	230	384	191	95.9
Cost of Revenue
Gross Profit	4.28	111	156	65.3	17.9
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	19.4	181	292	153	57.3
Operating Profit	-2.62	49.3	92.7	37.9	38.7
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3.95	88	147	173	-72.6
Provision for Income Taxes
Net Income After Taxes	4.57	78.4	127	136	-71.5
Minority Interest
Net Income Before Extraordinary Items
Net Income	4.42	60.9	114	156	-71.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4.42	60.9	114	156	-71.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.07	0.937	1.21	0.312	-0.213
Dividends per Share